对比超声、超声溶栓与超声灌注在心血管疾病中的应用:转向诊疗一体化临床试验
本文综述对比超声在心血管疾病诊断与预后评估中的应用,阐述微泡空化效应在高功率下产生剪切力增强内皮依赖性灌注(超声灌注)及碎裂血栓(超声溶栓)的机制。已有临床试验在急性心肌梗死、卒中和外周动脉疾病中开展,常伴结局改善,正在进行的试验将决定该诊疗一体化技术能否成为再灌注治疗的有价值补充。
要点
- 对比超声不仅用于诊断,还可通过微泡空化效应实现超声溶栓和超声灌注治疗。
- 高功率超声下微泡振荡产生剪切力增强内皮依赖性灌注,振荡塌陷诱导微流和射流碎裂血栓。
- 临床试验已在急性心肌梗死、卒中和外周动脉疾病中开展,常伴结局改善。
核心结论
- 对比超声的诊疗一体化技术(超声溶栓和超声灌注)在急性心肌梗死、卒中和外周动脉疾病临床试验中常伴结局改善,其价值待正在进行的试验确定。
研究设计与样本
- 综述性文章,总结临床前研究优化诊断超声设置和治疗方案,以及急性心肌梗死、卒中和外周动脉疾病的临床试验结果。
关键影像表现/征象
- 血管内对比微泡的显像基于声空化,即微泡特征性振荡导致反射超声波改变。
- 高功率下声学响应产生足够剪切力,可增强动脉粥样硬化血栓性心血管疾病的内皮依赖性灌注(超声灌注)。
- 微泡在超声作用下振荡和塌陷诱导微流和射流,可碎裂血栓(超声溶栓)。
临床应用与阅片要点
- 对比超声可用于心血管疾病诊断及预后信息评估,并可能通过调整超声功率实现治疗作用。
- 临床应用中需注意区分诊断用低功率显像与高功率治疗性空化效应。
局限性
- 原文为综述,未报告具体研究设计细节及定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Contrast ultrasound has a variety of applications in cardiovascular medicine, both in diagnosing cardiovascular disease as well as providing prognostic information. Visualization of intravascular contrast microbubbles is based on acoustic cavitation, the characteristic oscillation that results in changes in the reflected ultrasound waves. At high power, this acoustic response generates sufficient shear that is capable of enhancing endothelium-dependent perfusion in atherothrombotic cardiovascular disease (sonoperfusion). The oscillation and collapse of microbubbles in response to ultrasound also induces microstreaming and jetting that can fragment thrombus (sonothrombolysis). Several preclinical studies have focused on identifying optimal diagnostic ultrasound settings and treatment regimens. Clinical trials have been performed in acute myocardial infarction, stroke, and peripheral arterial disease often with improved outcome. In the coming years, results of ongoing clinical trials along with innovation and improvements in sonothrombolysis and sonoperfusion will determine whether this theragnostic technique will become a valuable addition to reperfusion therapy.
引用
- El Kadi S, Porter TR, Verouden NJW, et al. Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials. JACC Cardiovasc Imaging. 2021. PMID: 34656483. doi:10.1016/j.jcmg.2021.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。